Erin E. Atkins

Client Work

Erin’s clients include health care providers (including  pharmacies), brand and generic pharmaceutical manufacturers, medical device manufacturers, and independent patient assistance charities. Her recent work has included:

• Managing the production of a 50 state survey related to privacy laws. 
• Managing a comprehensive database of reporting requirements related to state drug pricing transparency.
• Drafting policies and procedures necessary for the establishment of an effective compliance program for a device manufacturer.
• Drafting and negotiating rebate agreements for both brand and generic pharmaceutical companies.
• Drafting and negotiating distribution agreements for pharmaceutical manufacturers.
• Drafting and negotiating GPO agreements for pharmaceutical manufacturers.
• Reviewing and revising policies and procedures related to government price reporting.
• Drafting and negotiating discount and services agreements with specialty pharmacies on behalf of pharmaceutical manufacturers.
• Providing regulatory support and guidance during internal investigations related to an entity’s compliance with their OIG Advisory Opinion.
• Drafting comments to proposed rules and regulations impacting participants in the pharmaceutical industry.

Previous Work

Prior to joining ArentFox Schiff, Erin was an associate at several international law firms, where she practiced in health care and life sciences. Prior to her career as a health care attorney, Erin’s practice was focused on capital markets, commercial real estate, and global finance.

Professional Activities

Erin is a member of the American Health Lawyers Association, and the Health Law Sections of both the District of Columbia Bar Association and the North Carolina Bar Association. Erin is also a member of the National Association of Women Lawyers.

Publications, Presentations & Recognitions

Erin frequently contributes to the ArentFox Schiff health care blog, Health Care Counsel, on regulatory developments and fraud and abuse issues germane to the pharmaceutical industry. Erin’s independently published articles include:

• “Cleaning House: CMS Proposes Sweeping Reform of Requirements for Long Term Care Facilities," California Healthcare News; October 2, 2015

Erin’s presentations include:

• Presenter, “Breaking Down the Latest Changes in US Drug Pricing and the Potential Impact on the Canadian Market,” The Canadian Institute’s Pathways To Access & Reimbursement Forum; January 20, 2023 (Hybrid)
• Presenter, “Redefine Relationships between Manufacturers and 501(c)3 Foundations,” CBI’s PAP Legal Update; September 25, 2018 (Arlington, VA)
• Moderator, “Implications of State Drug Pricing Transparency Laws on Policy,” 2nd Annual Drug Pricing Transparency Congress; March 22, 2018 (Philadelphia, PA)
• Panelist, “Legal and Compliance Considerations for Patient Assistance Programs,” 19th Annual Patient Assistance and Access Programs (PAP 2018); March 6, 2018 (Baltimore, MD)
• Co-Presenter, “Mitigate Risk in Patient Engagement and Support Programs through Proactive Monitoring,” 6^th Annual Compliance Monitoring 2018 Conference; February 27, 2018 (Philadelphia, PA)
• Co-Presenter, “340B Guidance Implications and Intersection with Medicaid Managed Care,” Medicaid Drug Rebate Program Conference; September 21, 2016 (Chicago, IL)
• Moderator, “Year in Review – Manufacturer Perspectives on Implementing Change and Continuous Improvement within the 340B Program,” CBI 340B Manufacturer Summit; August 19, 2016 (Washington, DC)
• Co-Presenter, “Long-Term Care Fundamentals,” American Bar Association; August 20, 2015 (Webinar)